Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...
Vertex VRTX reported third-quarter results highlighted by strong uptake of its cystic fibrosis triple combination therapy, Trikafta/Kaftrio, in the United States and internationally. Quarterly product ...
-More than 1,200 children are newly eligible for a medicine that could treat the underlying cause of their disease- About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...
Vertex Pharmaceuticals Incorporated VRTX is scheduled to release fourth-quarter and full-year 2023 results on Feb 5, after market close. The company has an impressive earnings surprise history, ...
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...
Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and ...
Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback